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different techniques to deal with missing data was compared.
METHODS: The analysis addressed the global health status
scale (QL range [1;100]) of QLQ-C30, the EQ-5D utility index
(Utility range [0;1]) and Visual Analysis Scale (VAS range
[0;100]). Five multiple imputation (MI) techniques were carried
out with two softwares (SAS, IVEware) and compared with
Rubin’s efﬁciency: Monte-Carlo Markov Chain (MCMC),
Expectation-Maximization (EM), Regression (REG), Propensity
score (PROP) and Sequential regression (SEQ), using 5 simula-
tions per technique. RESULTS: Changes signiﬁcance varied
depending on the imputation technique. At baseline, mean scores
were: QL 0.73, EQ-5D index 63.4, and VAS 68. For QL score,
the change estimations were (mean [95%CI]): -1.699 [-3.322;
-0.076] (MCMC), -1.558 [-3.132; 0.015] (EM), -1.795
[-3.449; -0.141] (REG), -1.197 [-3.067, 0.673] (PROP),
-0.895 [-5.622; 3.832] (SEQ). For EQ-5D index, estimations
were: -0.020 [-0.042; 0.003] (MCMC), -0.018 [-0.043; 0.007]
(EM), -0.018 [-0.034; -0.002] (REG), -0.015 [-0.045; 0.014]
(PROP), -0.010 [-0.049; 0.030] (SEQ). VAS changes varied
from 0.019 (SEQ) to 0.791 (PROP), no change estimation was
signiﬁcant. Rubin’s efﬁciency was comprised between 88.32%
and 94.43% depending on score and technique. CONCLU-
SIONS: Results have to be carefully interpreted since they vary
according to the MI method. SEQ is the only method not assum-
ing a normal distribution of the data and consequently displays
large conﬁdence intervals. Nevertheless, multiple imputation is
told to be robust to normality. A sensitivity analysis is advised in
order to compare the different results.
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OBJECTIVES: Whilst a number of systematic reviews (e.g.
Gotay et al in press) have been analyzing prognostic value of
patient-reported outcomes (PROs), including HRQOL, few have
focused on the statistical methods used. In this study, we
reviewed the statistical methods employed and proposed robust
statistical analysis for future PROs studies predicting survival of
cancer patients. METHODS: A total of 49 English articles were
selected from published reviews, conference abstracts, Medline
(1990–2008), various databases and discussions with colleagues
and reviewed during June to December 2007. Each article was
systematically examined for a key set of factors such as design
issues, selection of HRQOL factors, control for clinical factors
along with a detailed extraction of the statistical methods used
for analyzing HRQOL data. Once compiled, we identiﬁed good
practice and recommended approaches for future research.
RESULTS: Most HRQOL prognostic factor analyses, often
within clinical trials, are not deﬁned in protocols. In addition, a
detailed description of the statistical methodology and reporting
of the HRQOL results was often lacking in publications. Infor-
mation regarding sample size, handling missing data and the
veriﬁcation of the model assumptions varied considerably. Pre-
selection of HRQOL factors was not always done. A large
number of HRQOL factors increases the risk of selecting a factor
by chance and model over ﬁtting. In the model building strategy,
several approaches controlled for clinical factors in the analysis,
others allowed clinical factors replacement with (perhaps
slightly) more prognostic HRQOL factors. Model validation was
reported in nine studies. Measures of predictive accuracy were
computed in only seven studies. CONCLUSIONS: Undertaking
HRQOL prognostic factor analysis is a challenge. The priority is
validation and careful use of techniques and providing proof that
the addition of HRQOL indicators signiﬁcantly increases the
prediction of survival in cancer patients. We hope our work will
highlight these opportunities.
DIABETES/ENDOCRINE DISORDERS—
Clinical Outcomes Studies
PDB1
THE IMPACT OF INSULIN DETEMIR COMPAREDTO NEUTRAL
PROTAMINE HAGEDORN INSULIN ON LONG-TERM
DIABETES-RELATED COMPLICATIONS:A MODELING
ANALYSIS INTYPE 1 DIABETES PATIENTS IN BELGIUM,
FRANCE, GERMANY, ITALY AND SPAIN
Gschwend MH1,Aagren M2,Valentine WJ1
1IMS Health, Allschwil, Switzerland, 2Novo Nordisk A/S,Virum,
Denmark
OBJECTIVES: The aim of this analysis was to evaluate the time
to onset and long-term cumulative incidence of diabetes-related
complications in type 1 diabetes patients receiving either insulin
detemir or Neutral Protamine Hagedorn (NPH) insulin in com-
bination with mealtime insulin aspart in ﬁve countries (Belgium,
France, Germany, Italy and Spain). METHODS: A published and
validated computer simulation model of diabetes (CORE Diabe-
tes Model) was used to make long-term projections of clinical
outcomes, based on patient characteristics and treatment effects
from a 2-year, multi-national, open-label, randomized, con-
trolled trial. In the trial, insulin detemir was associated with
signiﬁcant improvements in glycemic control after 24 months
(HbA1c 7.36% versus 7.58%, mean difference -0.22%,
P = 0.022) and major hypoglycemic events (69% risk reduction,
P = 0.001) versus NPH. Patients treated with detemir gained less
weight (1.7 versus 2.7 kg, P = 0.024). Events were projected for
a time horizon of 50 years. RESULTS: Basal-bolus therapy with
insulin detemir was projected to improve mean life expectancy by
0.09 years (12.80 versus 12.71 years) versus NPH in Germany.
Similar beneﬁts were observed in the other countries
(Belgium + 0.14, France + 0.13, Italy + 0.15 and Spain + 0.07
years). The time to onset of any diabetes-related complication
was delayed by 0.08 years in the detemir arm (1.18 versus 1.10
years). Time to onset and cumulative incidence (CI) of diabetic
eye and renal disease, neuropathy and amputations were gener-
ally decreased for detemir-based therapy, with greatest beneﬁts
observed in renal disease. The CIs of heart failure, angina and
stroke were slightly raised in the detemir-based treatment arm as
overall survival was increased, exposing these patients to a longer
ongoing risk of these events. CONCLUSIONS: The modelling
analysis suggests that insulin detemir is likely to improve life
expectancy, delay the onset of and reduce the cumulative inci-
dence of most diabetes related complications in type 1 diabetes
patients.
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OBJECTIVES: This study investigated the effect on glycaemic
control of switching from a NPH-based regimen to a glargine-
based regimen in 701 patients with type 1 (T1) (n = 304) or type
2 (T2) (n = 397) diabetes, using unselected primary care data.
METHODS: Data for this retrospective observational study were
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